|
Post by LosingMyBullishness on Jan 5, 2016 10:08:57 GMT -5
Has anyone found the link to the conference call at mannkind's site?
|
|
|
Post by suebeeee1 on Jan 5, 2016 10:09:50 GMT -5
MannKind will host a conference call at 4:30 pm (Eastern Time) on January 5, 2016. To participate in the live call by telephone, please dial (888) 771-4371 FREE or (847) 585-4405 and use the participant passcode: 4155 4306. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at www.mannkindcorp.com. A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 FREE or (630) 652-3042 and use the participant passcode: 4155 4306#. A replay will also be available on MannKind's website for 14 days.
|
|
|
Post by mindovermatter on Jan 5, 2016 10:11:38 GMT -5
I'm just speculating but SNY's termination of the deal might be hardball tactic of getting Mannkind to sell Afrezza for cheap to them. SNY knew Al wouldn't sell for a lower price so what does SNY have to lose by terminating the deal and putting the screws to a financially strapped Mannkind to sell Afrezza for a much lower price than what Al wants?
|
|
|
Post by bradleysbest on Jan 5, 2016 10:11:55 GMT -5
I noticed that too.....
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 5, 2016 10:12:20 GMT -5
For a brief moment yesterday when I realized the new CEO's start date was the same day SNY could terminate I thought this was happening but then said don't be foolish. I am pretty disappointed but I am young and didn't have my life savings in this stock. I learned some hard lessons today and unfortunately my family who is in finance told me you don't invest in user reviews.
|
|
|
Post by silentknight on Jan 5, 2016 10:18:51 GMT -5
I'm just speculating but SNY's termination of the deal might be hardball tactic of getting Mannkind to sell Afrezza for cheap to them. SNY knew Al wouldn't sell for a lower price so what does SNY have to lose by terminating the deal and putting the screws to a financially strapped Mannkind to sell Afrezza for a much lower price than what Al wants? They'd never do this. By terminating the partnership, Sanofi now has NO rights to Afrezza, freeing up Al and the board to agree to a buyout with literally anyone else. Sanofi is bye-bye. They have no chance of ever retaining any rights to Afrezza or any TS application now. I still think SNY wanted to buy it, but they wanted it cheap, far cheaper than Al was willing to sell for, so they starved the launch intentionally in the hopes that MNKD would go bankrupt and they could but it in liquidation. They never made an attempt at commercialization. Something tells me that with a new CEO slated to take over on the day that the partnership was terminated, that there is some plan in the works. People have speculated that there may be another partner waiting in the wings, but I'm not sure. I do think we'll find one but I'm not sure there's one now. This is most assuredly NOT a negative development. SNY was doing nothing to make Afrezza a success and was not providing liquidity to ensure MNKD's operations. We just cut A LOT of dead weight. New CEO, new partner, new future. Today is a good day.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 5, 2016 10:20:34 GMT -5
I'm just speculating but SNY's termination of the deal might be hardball tactic of getting Mannkind to sell Afrezza for cheap to them. SNY knew Al wouldn't sell for a lower price so what does SNY have to lose by terminating the deal and putting the screws to a financially strapped Mannkind to sell Afrezza for a much lower price than what Al wants? They'd never do this. By terminating the partnership, Sanofi now has NO rights to Afrezza, freeing up Al and the board to agree to a buyout with literally anyone else. Sanofi is bye-bye. They have no chance of ever retaining any rights to Afrezza or any TS application now. I still think SNY wanted to buy it, but they wanted it cheap, far cheaper than Al was willing to sell for, so they starved the launch intentionally in the hopes that MNKD would go bankrupt and they could but it in liquidation. They never made an attempt at commercialization. Something tells me that with a new CEO slated to take over on the day that the partnership was terminated, that there is some plan in the works. People have speculated that there may be another partner waiting in the wings, but I'm not sure. I do think we'll find one but I'm not sure there's one now. This is most assuredly NOT a negative development. SNY was doing nothing to make Afrezza a success and was not providing liquidity to ensure MNKD's operations. We just cut A LOT of dead weight. New CEO, new partner, new future. Today is a good day.Agreed
|
|
|
Post by mindovermatter on Jan 5, 2016 10:22:57 GMT -5
I'm just speculating but SNY's termination of the deal might be hardball tactic of getting Mannkind to sell Afrezza for cheap to them. SNY knew Al wouldn't sell for a lower price so what does SNY have to lose by terminating the deal and putting the screws to a financially strapped Mannkind to sell Afrezza for a much lower price than what Al wants? They'd never do this. By terminating the partnership, Sanofi now has NO rights to Afrezza, freeing up Al and the board to agree to a buyout with literally anyone else. Sanofi is bye-bye. They have no chance of ever retaining any rights to Afrezza or any TS application now. I still think SNY wanted to buy it, but they wanted it cheap, far cheaper than Al was willing to sell for, so they starved the launch intentionally in the hopes that MNKD would go bankrupt and they could but it in liquidation. They never made an attempt at commercialization. Something tells me that with a new CEO slated to take over on the day that the partnership was terminated, that there is some plan in the works. People have speculated that there may be another partner waiting in the wings, but I'm not sure. I do think we'll find one but I'm not sure there's one now. This is most assuredly NOT a negative development. SNY was doing nothing to make Afrezza a success and was not providing liquidity to ensure MNKD's operations. We just cut A LOT of dead weight. New CEO, new partner, new future. Today is a good day. SNY hasn't put out a PR about them terminating the deal. It's only been MNKD. Could it be some are misinterpreting the PR and that Mannkind terminated the deal with SANOFI and that MANNKIND's wording of the pr only means they were kind enough to letting Sanofi to determine the date? I figure we'll find out the exact details this afternoon.
|
|
|
Post by wmdhunt on Jan 5, 2016 10:24:00 GMT -5
This is where our Israeli friends, "Teva" step in? I think this is what may have been "in the works". Here we go folks. As stated by others, "the game is on".
|
|
|
Post by novafett on Jan 5, 2016 10:26:31 GMT -5
This partnership was only a year long correct? I'm making some assumptions here but I don't think the decision to cut ties was made any time recent. Just makes me think that they gave this 2 quarters, 3 at best to be a block buster and then tanked it. Honestly i'm not even sure they gave it that much effort. I really wonder if they bought it with the same intention all along, sandbag, hope it doesn't take off, wait for MNKD to get into dire straights, hope Al capitulates and pick it up for pennies on the dollar. Greed sucks.
|
|
|
Post by bradleysbest on Jan 5, 2016 10:32:51 GMT -5
Wouldn't that be a kicker if the partnership was terminated because SNY has bought out MNKD... Is that possible?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 5, 2016 10:35:58 GMT -5
I'm just speculating but SNY's termination of the deal might be hardball tactic of getting Mannkind to sell Afrezza for cheap to them. SNY knew Al wouldn't sell for a lower price so what does SNY have to lose by terminating the deal and putting the screws to a financially strapped Mannkind to sell Afrezza for a much lower price than what Al wants? Unless another company comes in and takes it away and then co-promotes Afrezza with a generic Lantus and bundles it to the payors which then further kills any money Sanofi was going to get with their biosimilar licensing deal to Lilly. Remember, Mannkind can get a temp to perm or contract salesforce in place within a few months. You get 100 - 200 really good reps and incentivize them with the right options, take away the big pharma bullshit and show them the opportunity to put real money in their pockets and then watch NRx #s. PS - make sure a few of those reps are on Afrezza so then they can talk about the label and real world personal experiences. 10,000 patients having results like Sam and the gang and word will spread like wildfire.
|
|
|
Post by nylefty on Jan 5, 2016 10:39:45 GMT -5
I'm just speculating but SNY's termination of the deal might be hardball tactic of getting Mannkind to sell Afrezza for cheap to them. SNY knew Al wouldn't sell for a lower price so what does SNY have to lose by terminating the deal and putting the screws to a financially strapped Mannkind to sell Afrezza for a much lower price than what Al wants? They'd never do this. By terminating the partnership, Sanofi now has NO rights to Afrezza, freeing up Al and the board to agree to a buyout with literally anyone else. Sanofi is bye-bye. They have no chance of ever retaining any rights to Afrezza or any TS application now. I still think SNY wanted to buy it, but they wanted it cheap, far cheaper than Al was willing to sell for, so they starved the launch intentionally in the hopes that MNKD would go bankrupt and they could but it in liquidation. They never made an attempt at commercialization. Something tells me that with a new CEO slated to take over on the day that the partnership was terminated, that there is some plan in the works. People have speculated that there may be another partner waiting in the wings, but I'm not sure. I do think we'll find one but I'm not sure there's one now. This is most assuredly NOT a negative development. SNY was doing nothing to make Afrezza a success and was not providing liquidity to ensure MNKD's operations. We just cut A LOT of dead weight. New CEO, new partner, new future. Today is a good day. I agree that it's a good day. Just bought another 2000 shares.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 5, 2016 10:42:15 GMT -5
Wouldn't that be a kicker if the partnership was terminated because SNY has bought out MNKD... Is that possible? You cant be serious
|
|
|
Post by mnkdmorelong on Jan 5, 2016 10:43:46 GMT -5
I'm just speculating but SNY's termination of the deal might be hardball tactic of getting Mannkind to sell Afrezza for cheap to them. SNY knew Al wouldn't sell for a lower price so what does SNY have to lose by terminating the deal and putting the screws to a financially strapped Mannkind to sell Afrezza for a much lower price than what Al wants? They'd never do this. By terminating the partnership, Sanofi now has NO rights to Afrezza, freeing up Al and the board to agree to a buyout with literally anyone else. Sanofi is bye-bye. They have no chance of ever retaining any rights to Afrezza or any TS application now. I still think SNY wanted to buy it, but they wanted it cheap, far cheaper than Al was willing to sell for, so they starved the launch intentionally in the hopes that MNKD would go bankrupt and they could but it in liquidation. They never made an attempt at commercialization. Something tells me that with a new CEO slated to take over on the day that the partnership was terminated, that there is some plan in the works. People have speculated that there may be another partner waiting in the wings, but I'm not sure. I do think we'll find one but I'm not sure there's one now. This is most assuredly NOT a negative development. SNY was doing nothing to make Afrezza a success and was not providing liquidity to ensure MNKD's operations. We just cut A LOT of dead weight. New CEO, new partner, new future. Today is a good day. El Wrongo! The cancellation was big time negative! If Afrezza had any value in the insulin market, SNY would never have cancelled. Tim Tebow, the Heisman winning QB from Florida was found to have inferior NFL QB skills. He no longer plays. Same with Afrezza; it failed as an every day prandial.
|
|